Pfizer reports strong sales growth for breast cancer drug Ibrance in Q2

Pfizer has announced its sales figures for the second quarter of 2017, which show a slight fall in overall revenue from $13.15 billion (9.9 billion pounds) in Q1 to $12.9 billion.

A significant proportion of the pharmaceutical giant's Q2 revenue was attributed to its strong-performing breast cancer treatment Ibrance, for which sales grew by 66 percent between April and June.

Overall, Ibrance generated sales worth some $853 million, well above the initial predictions of $758 million. Xeljanz, Pfizer's rheumatoid arthritis treatment, also surpassed sales expectations, accounting for $366 million of the company's total revenue for Q2.

Ian Read, chief executive officer of Pfizer, explained that despite the slight dip in overall revenue in the last quarter, the firm is optimistic for the future, with "a strong pipeline" of innovative products in the works that it hopes will boost sales in the coming months and years.

"Over the next five years, we project the potential for approximately 25 to 30 approvals, of which up to 15 have the potential to be blockbusters," he stated.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Image credit: anyaberkut via iStock